Open Access64 Cu-based Radiopharmaceuticals in Molecular Imaging
Author(s) -
Zhou Yeye,
Li Jihui,
Xu Xin,
Zhao Man,
Zhang Bin,
Deng Shengming,
Wu Yiwei
Publication year - 2019
Publication title -
technology in cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 63
ISSN - 1533-0338
DOI - 10.1177/1533033819830758
Subject(s) - copper , positron emission tomography , radiochemistry , chemistry , chelation , molecular imaging , radionuclide , radionuclide imaging , cyclotron , nuclear medicine , medicine , nuclear physics , inorganic chemistry , ion , physics , in vivo , biology , organic chemistry , microbiology and biotechnology
Copper-64 (T 1/2 = 12.7 hours; β + : 19%, β − : 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom